VivoSeq
Other

Convulsion

6

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Convulsion is an early-stage landscape with 6 programs across 3 companies. The most active players are Vicuron Pharmaceuticals, UCB, Akero Therapeutics. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vicuron Pharmaceuticals

1 program

ApprovedUCB logo

UCB

2 programs

ApprovedAkero Therapeutics logo

Akero Therapeutics

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions
Completed·KKamuzu University of Health Sciences·Phase 3·NCT00116064·156 enrolled
Intermittent Levetricetam in Treatment of Febrile Convulsions
Unknown status·—·N/A·NCT05860153·100 enrolled
THE EFFECT OF THE TRAINING GIVEN TO THE PARENTS OF CHILDREN WITH FEBRILE CONVULSION WHO COME TO THE PAEDIATRIC EMERGENCY DEPARTMENT ON THE ANXIETY AND KNOWLEDGE LEVEL OF THE PARENTS
Completed·Uskudar University·N/A·NCT06676020·66 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)